Kelun-Biotech's Sacituzumab tirumotecan (Sac-TMT) has received marketing approval in China for treating advanced or metastatic triple-negative breast cancer (TNBC).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.